



**Statement of stand-alone Financial Results for the quarter ended 30<sup>th</sup> June, 2013**

*Rs. lakhs*

<b>PART I : STATEMENT OF STAND-ALONE RESULTS</b>				
<b>PARTICULARS</b>	<b>THREE MONTHS ENDED</b>			<b>YEAR ENDED (AUDITED)</b>
	<b>30-JUN-2013 REVIEWED</b>	<b>31-MAR-2013 UN-AUDITED</b>	<b>30-JUN-2012 REVIEWED</b>	<b>31-MAR-2013</b>
01. Gross Sales / Income from Operations	14254	13536	11663	54656
Less : Excise Duty	291	435	478	2122
Less : Sales Tax	278	278	327	1101
Net Sales / Income from Operations	13685	12823	10858	51433
02. Other Operating Income	797	1508	504	4492
03. TOTAL INCOME FROM OPERATIONS	14482	14331	11362	55925
04. EXPENDITURE				
a) Cost of materials consumed	3871	4774	4438	18063
b) Purchases of stock-in-trade	-	70	195	558
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-275	-690	-1389	-2125
d) Employee benefits expense	2205	2087	1928	8536
e) Depreciation and amortization expense	641	536	432	1984
f) Other Expenses	4172	4688	3306	15201
TOTAL EXPENSES	10614	11465	8910	42217
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	3868	2866	2452	13708
06. Other Income	350	203	301	1194
07. Finance costs	958	769	444	2512
08. Exceptional Items	-	-	-	1158
08. Profit / (Loss) from ordinary activities before tax	3260	2300	2309	11232
09. Tax expense, including deferred tax	986	1128	491	3419
10. Net Profit / Loss (-) from ordinary activities after tax	2274	1172	1818	7813
11. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137
12. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				50621
13. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	7.25 7.25	3.74 3.74	5.84 5.84	25.02 24.91
<b>PART II : SELECT INFORMATION</b>				
14. Public Shareholding:				
a) Number of Shares	13,607,593	13,594,593	13,378,081	13,594,593
b) Percentage of Shareholding	43.37	43.33	42.95	43.33
15. Promoters and Promoter Group Shareholding				
a) Pledged / Encumbered –	-	-	-	-
b) Non – encumbered – No. of shares	17,765,481	17,778,481	17,769,881	17,778,481
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	56.63	56.67	57.05	56.67

Dated at Hyderabad, this, the 14<sup>th</sup> day of August, 2013.  
for and on behalf of the Board of Directors,  
**NATCO** Pharma Limited

V.C. Nannapaneni  
Chairman & Managing Director

Status of Investor Complaints as at 30th June, 2013

Pending as on 01-04-2013	Nil
Received during the quarter	58
Resolved during the quarter	58
Pending as on 30-06-2013	Nil



**Statement of consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2013**

Rs. lakhs

<b>PART I : STATEMENT OF CONSOLIDATED RESULTS</b>				
<b>PARTICULARS (REFER NOTES BELOW)</b>	<b>THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)</b>			<b>YEAR ENDED (AUDITED)</b>
	<b>30-JUN-2013</b>	<b>31-MAR-2013</b>	<b>30-JUN-2012</b>	<b>31-MAR-2013</b>
01. Gross Sales / Income from Operations	17062	16156	14252	65302
Less : Excise Duty	323	430	478	2122
Less : Sales Tax	285	278	327	1101
Net Sales / Income from Operations	16454	15448	13447	62079
02. Other Operating Income	797	1283	637	4322
03. TOTAL INCOME FROM OPERATIONS	17251	16731	14084	66401
04. EXPENDITURE				
a) Cost of materials consumed	5745	4794	6511	17757
b) Purchases of stock-in-trade	-	1586	195	8714
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-275	-755	-1389	-2191
d) Employee benefits expense	2589	2539	2143	10229
e) Depreciation and amortization expense	731	625	443	2212
f) Other Expenses	4724	5143	3726	16900
TOTAL EXPENSES	13514	13932	11629	53621
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	3737	2799	2455	12780
06. Other Income	350	186	178	1241
07. Finance costs	996	823	467	2631
08. Exceptional Item	-	-	-	1158
09. Profit / (Loss) from ordinary activities before tax	3091	2162	2166	10232
10. Tax expense, including deferred tax	1014	1321	491	3644
11. Minority Interest	101	-291	-32	-599
12. Net Profit / Loss (-) from ordinary activities after tax	2178	1132	1707	7187
13. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137
14. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				50217
15. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.)	6.94 6.94	3.61 3.61	5.48 5.48	23.01 22.91
<b>PART II : SELECT INFORMATION</b>				
16. Public Shareholding:				
a) Number of Shares	13,607,593	13,594,593	13,378,081	13,594,593
b) Percentage of Shareholding	43.37	43.33	42.95	43.33
16. Promoters and Promoter Group Shareholding				
a) Pledged / Encumbered – No. of shares	-	-	-	-
b) Non – encumbered – No. of shares				
Percentage (as a % of the total shareholding of promoter and promoter group)	17,765,481 100.00	17,778,481 100.00	17,769,881 100.00	17,778,481 100.00
Percentage (as a % of the total share capital of the company)	56.63	56.67	57.05	56.67

The above financial results were approved by the Audit Committee and the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 14<sup>th</sup> August, 2013. There are no exceptional and extraordinary items to be reported for the period under review. The stand-alone results are available on the company's web-site [www.natcopharma.co.in](http://www.natcopharma.co.in). In respect of reference relating to non-accounting of minimum alternate tax credit, the company will review the position during the current financial year.

Dated at Hyderabad, this, the 14<sup>th</sup> August, 2013.

for and on behalf of the Board of Directors,

**NATCO** Pharma Limited

V.C. Nannapaneni  
Chairman & Managing Director

**Status of Investor Complaints as at 30<sup>th</sup> June, 2013**

Pending as on 01-04-2013	Nil
Received during the quarter	58
Resolved during the quarter	58
Pending as on 30-06-2013	Nil



**Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter ended on 30<sup>th</sup> June, 2013**

*Rs. lakhs*

	THREE MONTHS ENDED			PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	30-JUN-2013	31-MAR-2013	30-JUN-2012	31-MAR-2013
<b>01. Segment Revenue (Net)</b>				
a) Bulk Chemicals	6370	6562	3970	23692
b) Formulations	6488	7572	7056	29367
c) Job Work	195	219	156	944
d) Unallocated	1841	254	659	3244
<b>Total</b>	<b>14894</b>	<b>14607</b>	<b>11841</b>	<b>57247</b>
Less : Inter-segment Revenue	412	276	479	1322
<b>Net Sales / Income from Operations</b>	<b>14482</b>	<b>14331</b>	<b>11362</b>	<b>55925</b>
<b>02. Segment Results : Profit (+)/Loss (-) before tax and interest</b>				
a) Bulk Chemicals	1517	1541	653	5527
b) Formulations	2186	3136	2925	12235
c) Job Work	139	129	116	728
d) Unallocated	1673	223	591	2915
<b>Total</b>	<b>5515</b>	<b>5029</b>	<b>4285</b>	<b>21405</b>
Less : a) Interest	958	769	444	2512
b) Other allocable expenditure	1647	2163	1833	8855
c) Unallocable Income	(350)	(203)	(301)	(1194)
<b>Total Profit Before Tax</b>	<b>3260</b>	<b>2300</b>	<b>2309</b>	<b>11232</b>
<b>03. Capital Employed (Segment Assets - Segment Liabilities)</b>				
a) Bulk Chemicals	37370	36375	33382	36375
b) Formulations	30873	32742	29671	32742
c) Job Work	156	94	118	94
e) Unallocated (Others)	-12367	-15453	-14606	-15453
<b>Total</b>	<b>56032</b>	<b>53758</b>	<b>48565</b>	<b>53758</b>

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 14<sup>th</sup> August, 2013. There are no extraordinary items to be reported for the period under review. In respect of non-accounting of minimum alternate tax credit, referred to in the review report, the company will evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. The figures for the quarter ended March 31, 2013 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures up to third quarter of the relevant financial year, except those relating to segment revenues and profitability.

Dated at Hyderabad, this, the 14<sup>th</sup> day of August, 2013.

for and on behalf of the Board of Directors,

**NATCO** Pharma Limited

V.C. Nannapaneni  
Chairman & Managing Director

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**